Sanofi to Distribute RSV Vaccine Early, Triples Production Capacity

Sanofi has announced that it will commence the distribution of its respiratory syncytial virus (RSV) vaccine, Beyfortus, in the early third quarter of this year. This move is aimed at ensuring a widespread supply of the vaccine ahead of the 2025-2026 RSV season, which typically runs from November to March. The early distribution will allow healthcare institutions to prepare for the vaccination campaign, which usually begins in early autumn. This proactive approach by Sanofi is designed to enhance the readiness of medical facilities and ensure that the vaccine is readily available when needed.

The company's decision to expedite the distribution process underscores its commitment to public health and its efforts to mitigate the impact of RSV, a virus that can cause severe respiratory illness, particularly in young children and the elderly. By taking this step, Sanofi is not only demonstrating its operational efficiency but also its dedication to safeguarding public health during critical periods.

Sanofi, in collaboration with AstraZeneca, has significantly increased its production capacity to meet the growing demand for Beyfortus. As the only option currently available to protect all infants from RSV, the supply of Beyfortus is crucial for healthcare institutions. The company has tripled its production capacity since the vaccine's launch in 2023 and has doubled the number of production sites. The current supply for this season matches the total amount distributed last year, with production continuing to ramp up.

Beyfortus has shown sustained high efficacy in protecting against RSV throughout the entire RSV season, backed by real-world evidence. The vaccine's demand has been steadily increasing since its market entry, highlighting its importance in preventing RSV infections. The early distribution of Beyfortus will provide healthcare providers with the confidence and resources needed to support their work effectively.